Latest Articles

Publication Date
Disease Severity- and Hormonal Status-Dependent Alterations of EGF and MIF in the Serum of Endometriosis Patients.

Endometriosis is the extrauterine engraftment of endometrium-like tissue, causing chronic pain. Complex sensory-vascular-immune interactions, including growth factors, cytokines, and neuropeptides, are implicated in its pathophysiology, but the mechanisms remain unknown. …

Published: July 12, 2025, midnight
ASCO Reading Room | More Precise Treatments for Rare Uterine Tumors - MedPage Today

ASCO Reading Room | More Precise Treatments for Rare Uterine Tumors MedPage Today

Published: July 9, 2025, 3:13 p.m.
Clinical challenge of benign metastasizing leiomyoma with cardiac and hepatic involvement: A case report.

Benign metastasizing leiomyoma (BML) is a rare disorder occurring in women with a history of uterine leiomyomas and having detection of leiomyomas in extrauterine locations. This case report describes a …

Published: July 7, 2025, midnight
Chennai pvt hospital relieves woman with 2 tumorous wombs of pain - dtnext

Chennai pvt hospital relieves woman with 2 tumorous wombs of pain dtnext

Published: June 26, 2025, 1:20 a.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - BioSpace

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial BioSpace

Published: June 2, 2025, 11:48 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - GlobeNewswire

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial GlobeNewswire

Published: June 2, 2025, 6:32 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - Yahoo Finance

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial Yahoo Finance

Published: June 2, 2025, 6:30 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - Yahoo

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial Yahoo

Published: June 2, 2025, 6:30 p.m.
Serous Borderline Ovarian Tumor and Extensive Abdominopelvic Endometriosis Mimicking Advanced Epithelial Ovarian Cancer in a Postmenopausal Patient - Frontiers

Serous Borderline Ovarian Tumor and Extensive Abdominopelvic Endometriosis Mimicking Advanced Epithelial Ovarian Cancer in a Postmenopausal Patient Frontiers

Published: May 16, 2025, 7:47 p.m.
DNA glycosylase (NEIL3) overexpression associated with low tumor immune infiltration and poor overall patient survival in endometrial cancer - Nature

DNA glycosylase (NEIL3) overexpression associated with low tumor immune infiltration and poor overall patient survival in endometrial cancer Nature

Published: May 10, 2025, 10:19 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!